Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover…
07 Jan 2026
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss drug, deepening ties between the two companies. The latest partnership…
07 Jan 2026
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer. The…
07 Jan 2026
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) for Augtyro (repotrectinib) to treat adult patients with solid tumours harbouring…
06 Jan 2026
CDC shrinks childhood vaccine recommendation list to mirror “peer nations”
The US Centers for Disease Control (CDC) has shifted its stance on childhood vaccination, having minimised its routine recommendation list to 11 vaccines. This is down significantly from the regulator’s…
06 Jan 2026
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera…
06 Jan 2026
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The…